Medpace Holdings (MEDP) Form 4 Filings

Susan E. Burwig, Medpace Holdings, Inc.’s Executive Vice President, Operations, exercised options for 328 common shares at $166.73 per share on October 26, 2026. She sold 16,060 common shares that day and 3,940 on October 27, 2026, at $677 per share. The sales were effected pursuant to a limit order she placed during an open window period; no Rule 10b5-1 plan is reported.

Medpace Holdings, Inc. executive vice president of operations Susan E. Burwig exercised options for 2,700 shares of common stock on October 21, 2026, at an exercise price of $166.73 per share. The option had vested in full on October 27, 2025. After the transaction, her reported direct holdings were 73,684 common shares and 328 employee stock options.

Medpace Holdings, Inc. Executive Vice President, Operations Susan E. Burwig exercised options for 3,000 common shares on October 12, 2026, at an exercise price of $166.73 per share. Afterward, she reported holding 70,984 common shares and 3,028 options. The transaction was not reported under a Rule 10b5-1 plan.

At Medpace Holdings, Inc., Executive Vice President of Operations Susan E. Burwig exercised options for 2,000 common shares on October 7, 2026, at an exercise price of $166.73 per share. The report records 2,000 options disposed and 2,000 common shares acquired in the exercise. Afterward, her reported direct holdings were 67,984 common shares and 6,028 options.

Medpace Holdings, Inc. (MEDP) director Cornelius P. McCarthy III converted 28 restricted stock units into 28 shares of common stock on September 30, 2026. His directly held common-stock position following the transaction was 12,303 shares.

Medpace Holdings, Inc. (MEDP) director Robert O. Kraft converted 32 restricted stock units into 32 shares of common stock on September 30, 2026. He held 987 common shares directly after the transaction. The units were part of a 130-unit award granted November 28, 2025, scheduled to vest in four approximately equal installments, including one on September 30, 2026.

Medpace Holdings, Inc. director Brian T. Carley converted 36 restricted stock units into 36 shares of common stock on September 30, 2026. After the transaction, he directly held 27,861 common shares and 35 restricted stock units. Each unit represents a contingent right to receive one share of MEDP common stock.

Medpace Holdings, Inc. President & CEO August J. Troendle reported direct sales of 26,701 common shares on September 29, 2026, at a weighted average of $621.02 per share, and 21,966 shares on September 30, 2026, at a weighted average of $625.47 per share. Both sales were effected through a limit order placed during an open window period; no Rule 10b5-1 plan is reported. A separate entry lists 4,733,019 shares held indirectly by Medpace Investors, LLC as of September 29, 2026. Troendle reported sole voting and investment control over those shares and disclaimed beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported direct sales of 2,410 common shares on September 28, 2026, at a weighted average price of $620.07 per share, and 154 shares on September 25, 2026, at $620.60 per share. A separate holding lists 4,733,019 shares held indirectly by Medpace Investors, LLC. Troendle is its sole manager and controlling unit holder, has sole voting and investment control, and disclaims beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported direct sales of 16,083 shares at a weighted average price of $628.64 on September 23, 2026, and 27,833 shares at a weighted average price of $621.33 on September 24, 2026. The sales were made through a limit order during an open window period; no Rule 10b5-1 plan is reported. Separately, a holding entry dated September 23, 2026 lists 4,733,019 shares held indirectly by Medpace Investors, LLC. Troendle has sole voting and investment control over those securities and disclaims beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) President & CEO, director and ten percent owner August J. Troendle sold 21,883 common shares on September 21, 2026, at a weighted average price of $623.2900 per share, and 49,018 shares on September 22, 2026, at a weighted average price of $628.1100 per share. The reported price ranges were $620.00 to $625.91 and $620.00 to $632.815, respectively. Both sales were made pursuant to a limit order placed during an open window period, and no Rule 10b5-1 plan is reported. Separately, Medpace Investors, LLC held 4,733,019 shares as of September 21, 2026. Troendle is the LLC’s sole manager and controlling unit holder, has sole voting and investment control, and disclaims beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) reported that President & CEO and ten percent owner August J. Troendle sold 10,880 shares of Common Stock on September 17, 2026 in an open-market sale at a weighted average price of $620.40 per share, effected pursuant to a limit order during an open window period.

After this transaction, Troendle directly held 504,273 shares of Medpace common stock and also had indirect ownership of 4,733,019 shares held by Medpace Investors, LLC, over which he has sole voting and investment control while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported open-market sales of Medpace common stock. On September 15, 2026, he sold 15,971 shares at a weighted average price of $620.84, and on September 16, 2026, he sold 8,770 shares at a weighted average price of $621.29, for total reported sales of 24,741 shares.

The trades were effected pursuant to a limit order during an open window period. Troendle also reports 4,733,019 shares of Medpace common stock held indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unitholder; he may be deemed to beneficially own those securities but disclaims beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) executive Susan E. Burwig, Executive Vice President of Operations, exercised employee stock options for 3,000 shares of common stock on September 15, 2026 at an exercise price of $166.73 per share. The option, which vested in full on October 27, 2025 and expires on October 27, 2026, was converted into common stock, increasing her directly held common shares to 65,984. Following this transaction she continues to hold 8,028 stock options directly, and no Rule 10b5-1 trading plan is reported.

Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold 650 shares of common stock on 2026-08-27 at a weighted average price of $620.27 per share in transactions effected pursuant to a limit order during an open window period. After this sale, he directly holds 539,894 shares. He is also the sole manager and controlling unit holder of Medpace Investors, LLC, which holds 4,733,019 shares; he may be deemed to indirectly beneficially own those shares but disclaims beneficial ownership except to the extent of his pecuniary interest.

For Medpace Holdings, Inc. (MEDP), director Robert O. Kraft reported an option exercise and same-day sale. On 2026-08-26, he exercised stock options for 3,858 shares of common stock at an exercise price of $84.36 per share, fully using an option that vested on May 13, 2021 and leaving 0 options from that grant outstanding. He then sold 3,858 common shares on the same date at a weighted average price of $617.81 per share, in multiple trades ranging from $617.73 to $618.43, and stands ready to provide detailed pricing information upon request.

Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold common stock in two open-market transactions. On August 26, 2026, he sold 4,000 shares at a weighted average price of $620.03 per share, in multiple trades between $620.00 and $620.54. On August 25, 2026, he sold 673 shares at a weighted average price of $620.38 per share, in multiple trades between $620.00 and $621.89. The sales were effected pursuant to a limit order placed during an open window period. The filing also notes indirect ownership of 4,733,019 shares held by Medpace Investors, LLC, over which Troendle has sole voting and investment control, while he disclaims beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) reported that President & CEO and ten percent owner August J. Troendle sold a total of 15,978 shares of common stock. On August 21, 2026, he sold 13,995 shares at a weighted average price of $624.45 per share, with individual trades ranging from $620.00 to $628.685, effected under a limit order placed during an open window period. On August 24, 2026, he sold 1,983 shares at a weighted average price of $620.23 per share, with trades ranging from $620.00 to $621.25.

The filing also reports an indirect holding of 4,733,019 shares of Medpace common stock held by Medpace Investors, LLC, for which Troendle is the sole manager with sole voting and investment control. He may be deemed to indirectly beneficially own these securities but disclaims beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) reported an insider equity transaction by Kevin M. Brady, its CFO & Treasurer. On August 20, 2026, he exercised employee stock options to acquire 3,400 shares of Common Stock at $138.87 per share and then sold 3,400 Common shares at $625.24 per share pursuant to a limit order placed during an open window period. Following the option exercise, he held 3,403 employee stock options of the same grant, which had vested in full on February 15, 2026 and carry an expiration date of August 15, 2027.

Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold common stock in two open-market transactions. On August 20, 2026, he sold 27,174 shares at a weighted average price of $618.79 per share, and on August 19, 2026, he sold 15,609 shares at a weighted average price of $606.47 per share. Both were executed pursuant to a limit order during an open window period and involved multiple trades within disclosed price ranges. Following these transactions, Troendle is reported to indirectly hold 4,733,019 shares through Medpace Investors, LLC, where he has sole voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. (MEDP) director Brian T. Carley reported selling 5,000 shares of Medpace common stock on 2026-08-19 in an open-market or private transaction at a weighted average price of $608.63 per share, with individual trades ranging from $608.30 to $609.62. After this transaction, Carley directly holds 27,825 shares of Medpace common stock. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.

For Medpace Holdings, Inc. (MEDP), director Fred B. Davenport Jr. reported exercising stock options for a total of 7,583 shares of common stock on 2026-08-19 at exercise prices of $84.36, $133.87 and $164.68 per share. On the same date, he sold 7,283 shares of common stock at a weighted average price of $606.15 per share, in multiple trades between $605.59 and $607.20. Following these transactions, 2,000 shares are reported as held indirectly by a trust for his benefit.

Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Common Stock totaling 11,824 shares over two days in August 2026. He sold 11,366 shares on August 12, 2026 at a weighted average price of $601.53 per share and 458 shares on August 13, 2026 at a weighted average price of $600.39 per share, both effected pursuant to a limit order during an open window period. The filing also reports 4,733,019 shares of Common Stock held indirectly through Medpace Investors, LLC, for which Troendle is the sole manager with voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. director Cornelius P. McCarthy III reported a sale of 1,140 shares of common stock on 2026-08-11 in a transaction coded as a sale in an open market or private transaction at $605.37 per share. Following this sale, his directly held position stands at 12,275 shares. The filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.

Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Medpace common stock. On August 10, 2026, he sold 5,534 shares at a weighted average price of $601.53 per share in multiple transactions between $600.00 and $602.73. On August 11, 2026, he sold 17,610 shares at a weighted average price of $605.11 per share in multiple transactions between $600.09 and $608.185, all pursuant to a limit order placed during an open window period. He also reports 4,733,019 shares of common stock held indirectly through Medpace Investors, LLC, where he has sole voting and investment control but disclaims beneficial ownership except to the extent of his pecuniary interest.

Medpace Holdings, Inc. director Cornelius P. McCarthy III exercised stock options for 3,858 shares of common stock on 2026-08-07 at an exercise price of $84.36 per share. He then reported acquiring the same number of common shares through the exercise and selling 795 shares of common stock at a reported price of $585.071 per share. The exercised option, which covered 3,858 underlying shares, had vested in full on May 13, 2021 and carried an expiration date of May 15, 2027.

August J. Troendle, President, CEO and 10% owner of Medpace Holdings, reported open-market sales of 7,238 common shares on July 27-28, 2026, executed under a limit order placed during an open window period. The trades comprised 3,728 shares at a weighted average price of $600.85 (range $600.00–$603.495) and 3,510 shares at a weighted average price of $600.01 (range $600.00–$600.45). A separate entry lists 4,733,019 common shares held indirectly by Medpace Investors, LLC, over which he has sole voting and investment control and may be deemed to indirectly beneficially own, while disclaiming beneficial ownership beyond his pecuniary interest. The filing states these transactions were not made under a Rule 10b5-1 trading plan.

Medpace Holdings, Inc. executive Susan E. Burwig, Exec. VP, Operations, reported selling 7,500 shares of Common Stock on 2026-07-28 at $600 per share in a transaction described as open market or private.

After the sale, she directly owned 62,984 shares. The trade was executed under a limit order placed during an open window period.

Medpace Holdings director Cornelius P. McCarthy III exercised restricted stock units into common shares. He acquired 28 shares of Medpace common stock through the conversion of restricted stock units, bringing his direct common stock holdings to 10,352 shares. Following this transaction, he continues to hold 56 restricted stock units that each represent a contingent right to receive one share of Medpace common stock upon future vesting.

Medpace Holdings, Inc. director Robert O. Kraft exercised restricted stock units into common shares as part of his equity compensation. On June 30, he converted 33 restricted stock units into 33 shares of common stock at a stated price of $0.0000 per share. After this transaction, he directly holds 955 common shares and 64 remaining restricted stock units. These units come from a November 28, 2025 grant of 130 restricted stock units scheduled to vest in four approximately equal installments through December 31, 2026.

Medpace Holdings director Brian T. Carley exercised 36 restricted stock units into common stock on June 30, 2026. Following the transaction, he holds 32,825 shares of common stock and 71 remaining restricted stock units. The RSUs come from a 143-unit grant made on November 28, 2025.

Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald reported an exercise-and-sell transaction in company stock. He exercised options covering 16,349 shares of common stock at $138.87 per share and sold 16,349 shares in an open-market sale at $450.00 per share pursuant to a limit order placed during an open window period. Following these transactions, he holds 20,343 common shares directly.

Medpace Holdings director Dani S. Zander received a stock option grant covering 1,110 shares of common stock at an exercise price of $415.27 per share. This is a compensation-related award, not an open-market trade, and represents a new derivative position for the director.

The option expires on May 15, 2033 and vests on the earlier of the day immediately before the first annual shareholder meeting following the grant date or the first anniversary of the grant date, as long as Zander continues serving on Medpace’s board through that vesting date.

Medpace Holdings, Inc. director Cornelius P. McCarthy III received a grant of stock options covering 1,110 shares of common stock at an exercise price of $415.2700 per share. These options expire on May 15, 2033 and are a compensation-related award, not an open-market purchase.

According to the footnote, the option vests on the earlier of the day immediately preceding the first annual shareholder meeting after the grant date or the first anniversary of the grant, subject to his continued service on the board. Following the reported transactions, he holds 10,324 shares of common stock directly.

Medpace Holdings, Inc. director Robert O. Kraft reported a new stock option award and his current share holdings. He received options to buy 1,110 shares of common stock at an exercise price of $415.27 per share, expiring on May 15, 2033. Following the award, he holds 922 shares of common stock directly. The option vests on the earlier of the day immediately before the first annual meeting after the grant date or the first anniversary of the grant date, subject to his continued service on the board.

Medpace Holdings, Inc. director Femida H. Gwadry-Sridhar received a grant of stock options covering 1,110 shares of common stock. The options have an exercise price of $415.27 per share and expire on May 15, 2033.

According to the terms, the option vests on the earlier of the day immediately preceding the first annual meeting of shareholders following the grant date, or the first anniversary of the grant date, subject to her continued service on the board of directors through the vesting date. Following this grant, she holds options for 1,110 shares directly.

DAVENPORT FRED B JR reported acquisition or exercise transactions in this Form 4 filing.

Medpace Holdings, Inc. director Fred B. Davenport Jr. received a grant of 1,110 stock options to buy common stock at $415.2700 per share, expiring on May 15, 2033. The options vest on the earlier of the day immediately preceding the first annual meeting following the grant date or the first anniversary of the grant, subject to his continued board service. Following this grant, he holds 3,498 shares directly and 2,000 shares indirectly through a trust.

Medpace Holdings, Inc. director Brian T. Carley reported an equity compensation award and updated holdings. He received a grant of stock options covering 1,110 shares of common stock with an exercise price of $415.27 per share, expiring on May 15, 2033.

The option vests on the earlier of the day immediately before the first Medpace annual meeting after the grant date or the first anniversary of the grant, subject to his continued service on the board. Following the reported transactions, Carley directly holds 32,789 shares of Medpace common stock and 1,110 stock options.

Troendle August J. reported acquisition or exercise transactions in this Form 4 filing.

Medpace Holdings, Inc. CEO August J. Troendle reported new equity awards and updated his holdings. He received 10,000 restricted stock units and 20,000 employee stock options, each tied to Medpace common stock. Both awards vest in full on the second anniversary of the grant date, subject to his continued employment.

Following these updates, Troendle holds 646,184 common shares directly and 4,733,019 common shares indirectly through Medpace Investors, LLC, where he has sole voting and investment control but disclaims beneficial ownership beyond his pecuniary interest.

Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald exercised employee stock options to acquire 3,500 shares of common stock at $138.87 per share. After this exercise, he directly holds 20,343 shares of common stock.

He also received equity compensation awards on the same date: 5,000 restricted stock units, each representing one share of Medpace common stock, and 10,000 employee stock options with a $410.54 exercise price expiring on April 24, 2033. The options that were exercised had vested in full on February 15, 2026, while the new RSUs and options vest in full on the fifth anniversary of the grant date, subject to his continued employment.

Medpace Holdings, Inc. disclosed that Executive Vice President of Operations Susan E. Burwig received new equity awards. She was granted 5,000 restricted stock units, each representing a contingent right to receive one share of MEDP common stock, and 10,000 employee stock options with an exercise price of $410.54 per share, expiring on April 24, 2033. Both the options and the restricted stock units vest in full on the second anniversary of the grant date, subject to her continued employment with Medpace or one of its subsidiaries. Following these transactions, she directly holds 70,484 shares of Medpace common stock, along with the newly granted awards.

Medpace Holdings, Inc. reported that CFO & Treasurer Kevin M. Brady exercised employee stock options for 7,000 shares of common stock at an exercise price of $138.87 per share, increasing his directly held common shares to 12,830.

On the same date, he received a grant of 5,000 restricted stock units, each representing a contingent right to one share of MEDP common stock, and a separate grant of 10,000 employee stock options with a $410.54 exercise price. The filing notes that the fully vested option exercised on April 24, 2026 had vested on February 15, 2026, while the new RSUs and options vest in full on the fifth anniversary of the grant date, subject to continued employment.

Medpace Holdings director Cornelius P. McCarthy III exercised restricted stock units that converted into 29 shares of common stock on March 31, 2026. The award was part of a 113-unit grant from November 28, 2025 that vests in four approximately equal installments through December 31, 2026. Following this vesting event, he directly owns 10,324 shares of common stock and 84 restricted stock units, each representing a contingent right to receive one share of Medpace common stock.

Medpace Holdings, Inc. director Robert O. Kraft exercised 33 restricted stock units into 33 shares of common stock on March 31, 2026. This reflects the first vesting installment from a November 28, 2025 grant of 130 restricted stock units scheduled to vest quarterly through December 31, 2026. Following the transaction, he holds 922 shares of common stock directly and 97 restricted stock units representing an equal number of potential future shares.

Medpace Holdings director Brian T. Carley exercised restricted stock units into common stock. On March 31, 2026, 36 restricted stock units converted into 36 shares at a stated price of $0.00 per share, bringing his direct common stock holdings to 32,789 shares and leaving 107 restricted stock units outstanding from a prior grant.

Medpace Holdings, Inc. executive vice president of operations Susan E. Burwig exercised employee stock options for 12,000 shares of common stock at an exercise price of $166.73 per share on March 18, 2026. The option had fully vested on October 27, 2025. Following the transactions, she owns 70,484 shares of common stock and 11,028 derivative securities directly.

Medpace Holdings, Inc. President Jesse J. Geiger exercised stock options and sold the resulting shares. He exercised options for 31,707 shares of common stock at an exercise price of $138.87 per share, then sold 31,707 shares in an open-market transaction at a weighted average price of $455.30 per share. Following these transactions, he holds 15,000 shares of Medpace common stock directly. The filing notes that the option vested in full on February 15, 2026 and that the sale price reflects multiple trades between $451.36 and $460.288 per share.

Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald exercised employee stock options for 3,500 shares on February 17, 2026. This option exercise converted into 3,500 shares of common stock at $138.87 per share. Following the transactions, he directly held 16,843 shares of common stock and 19,849 derivative securities.

The option referenced in the filing vested in full on February 15, 2026.

Medpace Holdings director Brian T. Carley exercised stock options to acquire 6,472 shares of common stock at $54.99 per share on 02/13/2026. Following this option exercise, he directly owned 32,753 shares of Medpace common stock. The exercised option had vested in full on May 14, 2020 and is now fully exhausted, with no derivative securities remaining from this grant.